US Patent 7399829 Variants of RANKL protein
Patent 7399829 was granted and assigned to Xencor on July, 2008 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Jamal El Yazal0
John R. Desjarlais0
Rene S. Hubert0
Shannon A. Marshall0
Edits on 14 Sep, 2023
Golden AI
Edits made to:
Article (+269 characters)
Article
Patent abstract
The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor—κB Ligand) proteins, which may be expressed solubly in E. coli, variants that act as RANKL antagonists, and methods for generating the same.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07399829 Variants of RANKL protein US Patent 7399829 Variants of RANKL protein
Infobox
Patent Number
073998290
Patent Number
73998290
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
073998290
Date of Patent
July 15, 2008
0Patent Application Number
103387850
Date Filed
January 6, 2003
0Official Website
Patent Primary Examiner
Edits on 9 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 30 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07399829 Variants of RANKL protein
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07399829
Date of patent
July 15, 2008
Patent application number
10338785
Date Filed
January 6, 2003
Patent primary examiner
Find more entities like US Patent 7399829 Variants of RANKL protein
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.